Sino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.
Swiss Sophia Genetics to expand globally
Latest NewsSwiss Sophia Genetics has raised $110m, to expand marketing of its AI-driven cancer and genetic disease decision support platform globally.
EIB and EC launch circular bioeconomy fund
Latest NewsThe European Commission (EC) and the European Investment Bank (EIB) have launched a circular bioeconomy fund with a target size of €250m.
·
Dewpoint Therapeutics raise $77m in Series B financing
Latest NewsA $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies.
Kurma Partners close diagnostics fund at €50m
Latest NewsThe only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at €50m.
Danish Galecto Inc. secures US$64m equity financing
Latest NewsDanish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital.
MosaMeat NV bags US$55m financing
Latest NewsMaastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m.
Green carbon footprint
OpinionIn September, Unilever announced a €1bn investment to improve the sustainability of its cleaning brands from the ground up. European Biotechnology spoke to Dr Neil Parry, R&D programme director of biotechnology and biosourcing at Unilever about the goals of Clean Future.
A Comprehensive Tool Set for COVID-19 Research
Sponsored PublicationsSino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.
New on Vifor Pharma board
AppointmentsSince September Gregory Oakes is a new Member of the Vifor Management Board and President North America of the Swiss pharmaceutical company.
Pureos Bioventures closes US$170m fund
Latest NewsNewly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers.